Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study. (nature.com)

Authors: Wang F … Xu RH Journal: Nature Communications Published: 2026-09-18 DOI: https://doi.org/10.1038/s41467-026-77705-8